Please assess the completion status of the following clinical trial:

Trial Title: Apotransferrin in Patients With β-thalassemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non-transfusion dependent β-thalassemia intermedia, defined as patients with microcytic anaemia in combination with an elevated HbA2 (\>2.5%) and a haemoglobin of \<6.2 mmol/L, or transfusion dependent β-thalassemia treated with a regular transfusion schedule.~* Age above≥ 17 years.~* Adequate renal and hepatic function tests~* WHO performance 0, 1 or 2.~* Signed informed consent.~Exclusion Criteria:~* Known with allergic reactions against human plasma or plasma products.~* Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, pulmonary disease).~* Cardiac dysfunction as defined by: myocardial infarction within the last 6 months of study entry, unstable angina, or unstable cardiac arrhythmias.~* Pregnant or lactating females.~* Known with IgA deficiency with anti-IgA antibodies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- human apotransferrin (Type: EXPERIMENTAL): Patients will receive an intravenous dose of human apotransferrin every two weeks for 14-18 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).